Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Cash from Operations (TTM): -69.38M for Sept. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
September 30, 2023 | -69.38M |
June 30, 2023 | -76.80M |
March 31, 2023 | -83.23M |
December 31, 2022 | -89.18M |
September 30, 2022 | -87.62M |
June 30, 2022 | -84.35M |
March 31, 2022 | -129.32M |
December 31, 2021 | -122.15M |
September 30, 2021 | -120.49M |
June 30, 2021 | -113.30M |
Date | Value |
---|---|
March 31, 2021 | -9.176M |
December 31, 2020 | -8.616M |
September 30, 2020 | 40.27M |
June 30, 2020 | 42.52M |
March 31, 2020 | -7.983M |
December 31, 2019 | -2.891M |
September 30, 2019 | -43.05M |
June 30, 2019 | -38.92M |
March 31, 2019 | -32.41M |
December 31, 2018 | -27.13M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-129.32M
Minimum
Mar 2022
42.52M
Maximum
Jun 2020
-55.76M
Average
-73.09M
Median
Cash from Operations (TTM) Benchmarks
Merck & Co Inc | 14.76B |
Axonics Inc | -10.47M |
Johnson & Johnson | 23.19B |
Boston Scientific Corp | 2.477B |
Ambrx Biopharma Inc (DELISTED) | -57.70M |